Close

PHARMASEAL Launches Engility CTMS, an Innovative Clinical Trial Management Platform for Unified Governance­

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

PHARMASEAL, anew provider of clinical trial management and governance solutions to enter the market, has launched Engility CTMS, the first product to be released from its Engility B2B platform.

With a focus on usability and rapid implementation, this innovative new generation clinical trial management system (CTMS) has been designed to increase the level of governance and control that organisations demand from their management systems to enable effective oversight of their clinical trials.

A key challenge to overcome in the design was to optimise the cost of software validation so that new innovations can be introduced easily for the benefit of customers. EngilityCTMS is engineered for change and benefits from extensive automation to deliver new features in a regulated industry,faster than current products. With an intuitive interface and a flexible cloud architecture, biopharmaceutical and medical device companies of all sizes can leverage affordable enterprise technology to fit their particular organisation model.

Commenting on the company’s introductionto the market and the launch of itsfoundation product EngilityCTMS, Daljit Cheema, CEO and Founderof PHARMASEAL said:  “We are extremely proud to finally launch our new company and release ourinnovativeCTMS product. Our collective passion for continuous innovation led to developing the Engility platformand our first product, EngilityCTMS.With Engility, we can enable more companies to improve their governance and oversight processes. PHARMASEAL has proven that by applying advanced engineering and automation, technology can streamline and consolidate complex trial management activities.

We are excited to introduce Engility to the world market.” For further information, please visit www.pharmaseal.co

About PHARMASEAL
PHARMASEAL was founded in 2016 by a team of industry leaders who share a vision to create smarter technologies and innovative products for the improvement of human health.  The company’s  firstproduct EngilityCTMS simplifies the management and control of clinical trials for biopharmaceutical and medical device companies. EngilityCTMS utilises advanced engineeringofferingenterprise management with rapid deployment, an intuitive user interface and interoperability with other eClinical applications to optimisetrial governance and oversight. Further information can be found at: www.pharmaseal.co

Latest stories